

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims, in which insertions are indicated by underlining and deletions are indicated by strikeouts or double bracketing.

1-57. (Canceled)

58. (Previously Presented) A method for delivering a glycosaminoglycan to a subject, comprising, administering to a pulmonary tissue of a subject an unformulated dry glycosaminoglycan having a mean diameter of 1-500 microns.

59-115. (Canceled)

116. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-200 microns.

117. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-53 microns.

118. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-5 microns.

119. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-53 microns.

120. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-106 microns.

121. (Currently Amended) The method of claim 58, wherein the glycosaminoglycan is a heparin, a heparan sulfate, or a low molecular weight heparin.

122-203. (Canceled)

204. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-500 microns.

205. (Canceled)

206. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-250 microns.

207. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 10-100 microns.

208. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-200 microns.

209. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 100-150 microns.

210. (Canceled)

211. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 20-53 microns.

212. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 53-75 microns.

213. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 75-106 microns.

214-222. (Canceled)

223. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-50 microns.

224. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-20 microns.

225. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-100 microns.

226. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 1-250 microns.

227. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-200 microns.

228. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a mean geometric diameter of 5-30 microns.

229. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of 0.01 - 0.4 g/cm³.

230. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of greater than 0.4 g/cm³.

231. (Previously Presented) The method of claim 58, wherein the unformulated dry glycosaminoglycan has a tap density of less than 0.4 g/cm³.

232-252. (Canceled)